May 19, 2017 – Executive search firm Carmichael Fisher has recruited Dr. Richard Hatchett as chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI). Principle consultant Tarquin Bennett-Coles led the assignment along with managing director Justin Hobday.
Dr. Hatchett joins the organization from the Biomedical Advanced Research & Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS), where he was deputy director and chief medical officer. Over his career he has led medical countermeasure development programs at BARDA and the U.S. National Institutes of Health (NIH). He has played leading roles at HHS and the White House in designing these programs as well as in planning for and responding to H5N1 avian influenza (bird flu), the 2009 H1N1 influenza pandemic, and the Ebola, MERS, and Zika epidemics.
“The board is delighted to offer Dr. Hatchett the position as the CEO of CEPI,” said professor K. Vijay Raghavan, chair of the interim CEPI board. “He has the right expertise and experience to take CEPI into the next and permanent phase of its work. His experience from public health preparedness, both from BARDA, NIH and previously from the White House, makes him very well equipped to deliver on the vision and mission of CEPI.”
“Dr. Hatchett is the right person to lead CEPI in this important next phase of its work, where the coalition will start implementation through its first investments,” said professor Peter Piot, vice chair of the interim CEPI board. “He will be able to make CEPI deliver on the vaccine development objectives as well as the wider agenda of global health security.”
“Richard Hatchett has just the right combination of scientific insight and governmental experience to lead CEPI,” said John-Arne Røttingen, interim CEPI CEO. “Adding to this, he is a pragmatic leader with great diplomatic skills, which is suitable for leading CEPI by engaging both private and public sector partners as well as civil society.”
The Coalition for Epidemic Preparedness Innovations has a clear mandate: to stop future epidemics by fast development of new vaccines. This means creating vaccines for diseases that could cause epidemics ahead of an outbreak, reducing the loss of life and lessening the social and economic impact of infectious disease outbreaks.
Established in 2002, Carmichael Fisher is an international executive search firm with over 100 consultants, researchers and support staff. The firm focuses on senior level recruitment with a particular focus on financial services, legal & professional services, life sciences, manufacturing, transport & infrastructure, energy, real estate, media and retail & consumer. The firm’s offices are in London, Brussels, Stockholm, Hamburg, Lagos, Dubai, Singapore, Sydney and Melbourne.
Mr. Bennett-Coles has more than 18 years of life science executive search and interim management experience. He has recently been working in partnership with biotech, digital health and rare and orphan disease SMEs (small and medium sized enterprises) as they commercialize across Europe and North America.
He handles senior general management, C-suite and board level roles within the commercial, medical, clinical, HR and country management functions of biotech, medtech, informatics, pharmaceutical, diagnostics and allied technology businesses. In addition, he has partnered with, and supported, relevant industry associations, the VC community and the not-for-profit sector.
Mr. Hobday joined Carmichael Fisher in 2008 as managing director to develop the firm’s EMEA region. Since then, he has overseen the expansion from a single office in London to six locations across Europe and Africa, with growth every year. His experience is international in scope and spans multiple sectors. He leads some of the firm’s most senior mandates as well as its work with non-executive appointments.
An Expanding Platform
Carmichael Fisher just recently expanded into the U.S. with the opening of an office in Los Angeles. The new location is led by Mr. Hobday and supported locally by two regional directors, new hire Kimberley Rice and Ciara Kelleher, who transferred from the firm’s EMEA headquarters in London.
In addition to its expansion to the U.S., the firm also opened a new office in Zurich. This becomes the firm’s seventh EMEA location and further cements its commitment to a single European proposition that allows for a seamless focus to conduct cross-border, pan-European work to identify and attract candidates from an international talent pool.
Contributed by Dale M. Zupsansky, Managing Editor – Hunt Scanlon Media